San Diego-based Eidogen-Sertanty said this week that it has signed a deal with AstraZeneca Pharmaceuticals to provide access to its informatics software. AstraZeneca Boston will use Eidogen-Sertanty's software to assist in drug discovery efforts in the area of cancer and anti-infective therapeutic programs. The company also said this week that it has established a collaboration with San Diego-based Kalypsys to use its computational drug discovery platforms for discovery of novel small molecules for anti-inflammatory indications. Eidogen-Sertanty is developing bioinformatics software for managing protein structural data and other areas. The company is backed by Tavistock, HighBAR Ventures, The Athenaeum Fund, and the Band of Angels.